Human Genome Sciences, Inc. (HGSI) Announces Delivery of Anthrax Treatment to U.S. Strategic National Stockpile
Today, Human Genome Sciences announced that it has begun delivering 20,000 doses of its human monoclonal antibody drug ABthrax(TM) (raxibacumab) to the U.S. Strategic National Stockpile. ABthrax, a first-in-class treatment for anthrax, is recognized as the first procurement under Project BioShield of a product discovered and developed after the September 11, 2001 terrorist attacks. "We believe ABthrax offers a significant step forward in the treatment of inhalation anthrax and could play an important role in strengthening America's arsenal against bioterrorism. From a business perspective, this announcement is strategically important for HGS, because it marks our Company's first product sales,” said…